Short answer
VERACYTE, INC. (VCYT) filed an 8-K current report with the SEC on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results announced for quarter ended September 30, 2026.
VERACYTE, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results announced for quarter ended September 30, 2026
- Investor focus: revenue, profitability, cash flow and updated outlook in Exhibit 99.1
Item 8.01 · Other Events
- $100 million share repurchase authorization, available over one year beginning November 4, 2026
- Potentially supports per-share metrics and signals management views shares as attractively valued
- Repurchases discretionary, with no obligation to buy shares and authorization subject to suspension or termination
- Funding competes with capital requirements, alternative investments and other corporate uses
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $151.8M, up 15%, with testing revenue $146.4M and gross margin improving to 71%
- Afirma revenue $51.5M, up 19%, outpaced Decipher Prostate at $92.3M, up 12%
- GAAP net income $31.5M, diluted EPS $0.38, and operating cash flow $40.3M
- 2026 revenue guidance narrowed to $590M-$593M, while testing revenue guidance fell to $571M-$573M
- New $100M buyback, funded from cash, signals capital-return confidence but competes with acquisition and pipeline investment needs
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other VERACYTE, INC. 8-K filings
Get the next VCYT 8-K as it lands
Follow VCYT for push alerts, or ask the research agent what this filing means.